Codexis unveils ECO Synthesis platform at TIDES USA for RNAi therapeutics production

Proprietary tech developed to address oligonucleotide manufacturing sustainability and scalability challenges.

Codexis has launched its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis technology, aimed at scaling up the manufacturing of RNA oligonucleotide therapeutics. The proprietary platform was unveiled at TIDES USA during a pre-conference workshop. Codexis is a leading enzyme engineering company and trades on the NASDAQ under the ticker symbol CDXS.

RNA therapeutics are gaining popularity as messenger RNA (mRNA) vaccines and small interfering RNA (siRNA) product candidates continue to advance in clinical trials. However, large-scale production poses challenges in terms of nucleic acids quality and quantity, as well as economics. Codexis aims to overcome these challenges with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis technology, which replaces phosphoramidite chemistry with enzymatic methods, allowing for scalable and sustainable manufacturing.

Codexis President and CEO, Stephen Dilly, has introduced the company's Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform at TIDES, saying that the enzymatic solution has the potential to enable scalable RNAi therapeutics production. He added that as RNA-based therapeutics are applied to larger disease indications, the current chemical synthesis route will become unsustainable, and customers have voiced the need for an enzymatic option. Codexis believes it is uniquely positioned for success in this emerging market due to its history of engineering complex enzymes for pharmaceutical manufacturing and relevant customer relationships.

Published on : 11th May, 2023